PA
KROS icon

Parallel Advisors’s Keros Therapeutics KROS Stock Holding History

Parallel Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4
Closed – – 3453
2022
Q3 		$0 Buy
+4
New +$139 ﹤0.01% 3337
2022
Q2 		– Sell
-44
Closed -$2K – 3181
2022
Q1 		$2K Buy
+44
New +$2.26K ﹤0.01% 2585

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Parallel Advisors's KROS Position: Q4 2022 in Review

Parallel Advisors sold out of Keros Therapeutics (KROS) in Q4 2022, closing a stake of 4 shares.

Parallel Advisors first reported a position in KROS in Q1 2022 and held it in 2 quarters. The position peaked at $2K in Q1 2022. 126 funds tracked by Wall St. Rank hold KROS as of Q4 2022.

  • Parallel Advisors reported no remaining Keros Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Parallel Advisors sold 4 Keros Therapeutics shares in Q4 2022.
  • Parallel Advisors first reported a position in Keros Therapeutics in Q1 2022 and held it in 2 quarters.
  • Parallel Advisors's Keros Therapeutics position peaked at $2K in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2022.

Based on Parallel Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.